Such a Deal, Late-Phase
Executive Summary
The cliché is that late-stage deals are necessarily expensive. Genentech is showing they don't have to be, lowering its cost of access to drugs by weighting most of its payments towards equity and milestones--and buying the drugs others pass over as too risky.